Cardiac medication may help reduce stiffness caused by certain muscle diseases

October 2, 2012

Preliminary research finds that for patients with nondystrophic myotonias (NDMs), rare diseases that affect the skeletal muscle and cause functionally limiting stiffness and pain, use of the anti-arrhythmic medication mexiletine resulted in improvement in patient-reported stiffness, according to a preliminary study in the October 3 issue of JAMA.

Data on treatment of NDMs are largely anecdotal, consisting of case series and a single-blind, controlled trials of several medications including mexiletine, according to background information in the article.

Jeffrey M. Statland, M.D., of the University of Rochester Medical Center, Rochester, New York, and colleagues in the Consortium for Clinical Investigation of Neurologic Channelopathies conducted a study to determine the effects of mexiletine for symptoms and signs of myotonia (prolonged failure of muscle relaxation after contraction) in patients with NDMs. The randomized study, part of the National Institutes of Health-funded Rare Disease Clinical Research Network, was conducted at seven neuromuscular referral centers in four countries between December 2008 and March 2011 and included 59 patients with NDMs. Patients (33 men, 26 women; average age, 43 years) received either oral 200-mg mexiletine or placebo capsules three times daily for four weeks, followed by the opposite intervention for four weeks, with 1-week washout in between. The main outcome measured for the study was patient-reported severity score of stiffness recorded on an (IVR) diary (scale of 1 = minimal to 9 = worst ever experienced). Secondary outcomes included IVR-reported changes in pain, weakness, and tiredness; clinical myotonia assessment; quantitative measure of handgrip myotonia; and Individualized Neuromuscular Quality of Life summary quality of life score (INQOL-QOL, percentage of maximal detrimental impact).

Data from 57 participants who made telephone calls to the IVR diary in weeks 3 to 4 of period 1 or 2 were included in the analysis. The researchers found that mexiletine was associated with significantly improved stiffness as reported on the IVR diary in both treatment periods. For period 1, the treatment effect was 2.53 for mexiletine vs. 4.21 for placebo; for period 2, 1.60 for mexiletine vs. 5.27 for placebo.

There were significant improvements with mexiletine in most other outcomes in the study, including patient-reported outcomes, quality of life scales, and quantitative measures of myotonia (improved myotonia as measured on clinical examination by overall handgrip times in seconds).

"The most common adverse effect was gastrointestinal (9 mexiletine and 1 placebo). Two participants experienced transient cardiac effects that did not require stopping the study (1 in each group). One serious adverse event was determined to be not study related," the authors write.

"Our study provides preliminary evidence of the effectiveness of mexiletine for symptoms and signs of myotonia in NDMs," the researchers write. "The clinical significance of the improvement in stiffness score on the IVR diary is supported by the broad improvement in clinical, quantitative, and electrophysiological measures of myotonia."

"The study by Statland et al provides important information that should help inform the treatment of patients with myotonia," writes Eric P. Hoffman, Ph.D., of the Children's National Medical Center, and Henry J. Kaminski, M.D., of George Washington University, Washington, D.C., in an accompanying editorial.

"The success of this trial should encourage the Consortium for of Neurologic Channelopathies (CCINC) group to take the lead with larger phase 3 trials. Even more exciting would be development of novel agents that can produce therapeutic benefit with much greater effect sizes. Most important, the National Institutes of Health, industry, and patient advocacy groups should attempt to replicate the success of the CCINC through establishment of more clinical research consortia focused on rare disorders."

Explore further: In muscular dystrophy, what matters to patients and doctors can differ

More information: JAMA. 2012;308[13]:1357-1365.
JAMA. 2012;308[13]:1377-1378.

Related Stories

In muscular dystrophy, what matters to patients and doctors can differ

July 25, 2012
Complex, multi-system diseases like myotonic dystrophy – the most common adult form of muscular dystrophy – require physicians and patients to identify which symptoms impact quality of life and, consequently, what ...

Acid reflux drug does not improve asthma in children

January 24, 2012
Children without symptoms of gastroesophageal reflux whose asthma was being poorly controlled with anti-inflammatory treatment did not have an improvement in symptoms or lung function with the added treatment of the proton ...

L-carnitine does not reduce cancer-related fatigue

September 18, 2012
(HealthDay)—Patients with invasive malignancies who take L-carnitine supplements do not experience a reduction in fatigue, pain, or depression, according to research published online Sept. 17 in the Journal of Clinical ...

Recommended for you

How genes and environment interact to raise risk of congenital heart defects

October 19, 2017
Infants of mothers with diabetes have a three- to five-fold increased risk of congenital heart defects. Such developmental defects are likely caused by a combination of genetic and environmental factors. However, the molecular ...

Mouse studies shed light on how protein controls heart failure

October 18, 2017
A new study on two specially bred strains of mice has illuminated how abnormal addition of the chemical phosphate to a specific heart muscle protein may sabotage the way the protein behaves in a cell, and may damage the way ...

Newborns with trisomy 13 or 18 benefit from heart surgery, study finds

October 18, 2017
Heart surgery significantly decreases in-hospital mortality among infants with either of two genetic disorders that cause severe physical and intellectual disabilities, according to a new study by a researcher at the Stanford ...

Saving hearts after heart attacks: Overexpression of a gene enhances repair of dead muscle

October 17, 2017
University of Alabama at Birmingham biomedical engineers report a significant advance in efforts to repair a damaged heart after a heart attack, using grafted heart-muscle cells to create a repair patch. The key was overexpressing ...

Physically active white men at high risk for plaque buildup in arteries

October 17, 2017
White men who exercise at high levels are 86 percent more likely than people who exercise at low levels to experience a buildup of plaque in the heart arteries by middle age, a new study suggests.

High blood pressure linked to common heart valve disorder

October 17, 2017
For the first time, a strong link has been established between high blood pressure and the most common heart valve disorder in high-income countries, by new research from The George Institute for Global Health at the University ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.